Tuesday, August 06, 2013 9:29:38 AM
LymPro has enormous potential and Gerald has indicated that its full speed ahead. They are going to add new talent and expertise and now have an solid relationship with Becton Dickinson to commercialize LymPro (what you need to understand is that Amarantus will retain full rights meaning they wont have to share the revenues or pay royalties at this time).
MANF programs will now be accelerated as they have identified Orphan indications to speed the process. It sounds very promising that their will be an IND sometime next year for one Orphan indication. Also, they have purchased a Phase IIb compound that will be developed within a year (for Parkinsons too).
Lastly, the capability to obtain the necessary funding/financing will now only increase as the company hits their milestones (I would not want any dilutive deals to occur down at these prices....we had enough dilution already).
Long term bulls will be happy to hear the positive news/update. The S/T flippers and quick buck artists will more than likely leave (and that's a good thing).
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM